Ascelia Pharma AB (publ) (ACE.ST)
Ascelia Pharma AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Malmö, SN, SE. The stock last traded at $0.64, up 2.23% on the session, giving a market capitalisation of $85.9M. Its beta of 0.85 implies it has historically moved less than the broad market.
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Ascelia Pharma AB (publ) is most often compared with the following Healthcare names: